"At UCSF Health, we're taking every precaution to keep you safe and healthy during the COVID-19 pandemic. For our outpatients, we offer video visits and virtual care for hundreds of conditions as well as for primary care, mental health services, medication monitoring and more. In our hospitals, we test every patient admitted and before most procedures. Our staff wears face masks and practices rigorous hand hygiene, as well as many other methods of infection prevention. Before entering your room, they'll make sure you're masked and (in UCSF Benioff Children's Hospitals) that your child age 2+ is masked. If you're planning to visit someone in the hospital, be sure to check our COVID-19 visitor restrictions before going."

During the past decade, Univ of Calif, San Francisco; Breast Cancer Center conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 1 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 1 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Univ of Calif, San Francisco; Breast Cancer Center" #1 collaborator was "Hoffmann-La Roche" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Univ of Calif, San Francisco; Breast Cancer Center" are "Breast Cancer" (2 trials), "Advanced Solid Tumors" (1 trials), "Breast Neoplasm" (1 trials), "Colorectal Cancer" (1 trials) and "Neoplasm Metastasis" (1 trials). Many other conditions were trialed in "Univ of Calif, San Francisco; Breast Cancer Center" in a lesser frequency.

Most popular intervention types in "Univ of Calif, San Francisco; Breast Cancer Center" are "Drug" (4 trials) and "Diagnostic Test" (1 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (2 trials), "Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody" (1 trials), "Bevacizumab" (1 trials), "Cetuximab" (1 trials) and "Docetaxel" (1 trials). Other intervention names were less common.

The vast majority of trials in "Univ of Calif, San Francisco; Breast Cancer Center" are 5 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Univ of Calif, San Francisco; Breast Cancer Center". undefined are not yet recruiting, 3 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Univ of Calif, San Francisco; Breast Cancer Center, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Univ of Calif, San Francisco; Breast Cancer Center, 1 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".